Primary aldosteronism is recognized as one of the most common drivers of secondary hypertension, affecting 4% to 22% of all hypertensive patients globally. This debilitating condition is predominantly caused by adrenal cortical abnormalities, most notably aldosterone-producing adenomas (APAs), which lead to the autonomous, unchecked secretion of the hormone aldosterone. While advanced imaging techniques have improved non-invasive diagnostics for these adrenal lesions, the complex internal signaling pathways fueling this hormonal overproduction have remained poorly understood.
This new research, published in Genes & Diseases by a scientific team from The First Affiliated Hospital of Chongqing Medical University and The Affiliated Hospital of Southwest Medical University, investigated the previously unrecognized role of the chemokine receptor CXCR4 in regulating aldosterone synthesis.
Through comprehensive in vitro molecular experiments utilizing lentiviral-mediated overexpression (LV-CXCR4) and targeted knockdown (LV-shCXCR4) systems, the researchers systematically evaluated adrenal cellular function and steroidogenic dynamics. The data revealed a striking regulatory mechanism: the strategic overexpression of CXCR4 inhibits the synthesis of aldosterone and suppresses the expression of CYP11B2, the crucial enzyme responsible for final aldosterone production. Conversely, genetically knocking down CXCR4 promoted aldosterone synthesis and elevated CYP11B2 levels.
To decode the specific intracellular networks driving this suppression, the research team employed advanced transcriptomic sequencing. The analysis unraveled a fascinating downstream cascade, demonstrating that CXCR4 exerts its strong inhibitory control primarily by heavily up-regulating the transcription regulator ID3 (inhibitor of DNA binding 3). Advanced molecular assays confirmed that this newly elevated ID3 acts as a powerful molecular brake within the cell. The data showed that the CXCR4-driven surge in ID3 directly inhibits CYP11B2 mRNA and protein expression, stripping the adrenal cells of their capacity to manufacture aldosterone. Furthermore, directly silencing ID3 effectively reversed the suppressive effects of CXCR4, decisively confirming its vital role in this novel signaling axis.
While these comprehensive data highlight the critical advantage of utilizing the CXCR4/ID3 network to manipulate steroid hormone biosynthesis, additional clinical evaluations are necessary to translate these targeted pathways into human therapies.
In conclusion, deciphering the CXCR4/ID3/CYP11B2 regulatory axis offers a powerful new strategy to combat autonomous hormonal overproduction. This substantial finding directly positions the therapeutic modulation of CXCR4 as a highly compelling candidate for developing next-generation, targeted treatments for patients suffering from primary aldosteronism and severe secondary hypertension.
Reference
Title of Original Paper: CXCR4 reduces aldosterone synthesis via regulating CYP11B2 expression
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2025.101956
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus Cite Score: 10.4 | Impact Factor: 14.6
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect ( https://www.sciencedirect.com/journal/genes-and-diseases ).
Submissions to Genes & Diseases may be made using Editorial Manager ( https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases ( https://x.com/GenesNDiseases )
Genes & Diseases